List view / Grid view
22 June 2015 | By Victoria White
Results from an interim analysis of a Phase III study demonstrate that idarucizumab immediately reversed the anticoagulant effect of dabigatran...
22 June 2015 | By Victoria White
Full results from the second part of a Phase 3 trial evaluating the safety and efficacy of andexanet alfa as a reversal agent of Eliquis have been announced...
22 June 2015 | By Victoria White
Pfizer has entered into an agreement with GlaxoSmithKline to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for $130 million...
22 June 2015 | By Victoria White
Results from a new sub-analysis of the Phase 3 Aethera clinical trial of Adcetris were presented at the 13th International Conference on Malignant Lymphoma...
22 June 2015 | By Victoria White
Epizyme has reported results from the ongoing Phase 1 trial of tazemetostat in patients with advanced B-cell non-Hodgkin's lymphoma and solid tumours...
22 June 2015 | By Victoria White
The European Commission has approved Bristol-Myers Squibb’s Opdivo, a PD-1 immune checkpoint inhibitor, for the treatment of advanced melanoma in adults...
22 June 2015 | By
CPhI China, hosted by UBM EMEA and CCCMHPIE, returns to the Shanghai New International Exhibition Centre, SNIEC, China from 24 to 26 June 2015...
20 June 2015 | By Celsis International
Celsis’ Accel System for Pharma allows products to be quickly released from micro hold, diminishing manufacturing cycle times and reducing inventory and working capital requirements...
19 June 2015 | By Eli Lilly and Company
Encouraging subgroup findings are basis for new phase III trial...
19 June 2015 | By AOP Orphan Pharmaceuticals AG
AOP Orphan Pharmaceuticals AG has announced the regulatory submission of Tetrabenazine for the treatment of tardive dyskinesia in a DCP (decentralized procedure) for several European countries with UK being reference member state...
19 June 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb has announced results from new post hoc analyses of the Phase 3b AVERT and AMPLE trials, which included early moderate to severe rheumatoid arthritis (RA) patients with active disease and markers of poor prognosis...
18 June 2015 | By Victoria White
Galapagos has completed recruitment for the Phase 2 Proof-of-Concept study in ulcerative colitis with GPR84 inhibitor GLPG1205...
18 June 2015 | By Victoria White
A new study shows that the antibiotic azithromycin, often prescribed to cure common infections, kills many multidrug-resistant bacteria very effectively...
18 June 2015 | By Victoria White
Lilly’s investigational medicine for the prevention of migraine, LY2951742, met the primary endpoint in a Phase 2b study in episodic migraine...
18 June 2015 | By Victoria White
NICE has opened a consultation on preliminary draft guidance for the drug idelalisib (Zydelig) for adults with chronic lymphocytic leukaemia...
